Case study: MolMed presents process development and large-scale GMP production for lentiviral (LV) and retroviral (RV) vectors in the iCELLis® 500 fixed-bed bioreactor
MolMed is a biotechnology company focused on research, development and manufacturing of innovative therapies to treat cancer and rare genetic diseases. MolMed has developed a robust and scalable process for the industrial scale production of both LV and RV vectors for use in gene-modified cell therapy using the iCELLis bioreactor platforms.
Molmed present the development and optimization of their LV and RV vector production processes in the scale down iCELLis nano bioreactor. The processes were then scaled up to the production scale iCELLis 500 bioreactor and results were comparable to processes performed at small scale.
Webinar participants learn: